Rituximab(RTX)is a monoclonal antibody specific for CD20 antigens on B cells and has been approved by the National Medical Products Administration for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukemia.In the clinical,RTX has been used in a variety of autoimmune-associated diseases,such as immune thrombocytopenia,Sjogren's syndrome,systemic lupus erythematosus etc.,all of which are beyond off-label drug use.The aim of this article is scientifically management of the off-label use of RTX based on international and domestic RTX medication instructions,guidelines,expert consensus,and trustworthy clinical trials.
维普
万方数据